ESR1 and breast carcinoma: Publicly available gene expression data of ER+/HER2− breast cancers from the pembrolizumab arm and corresponding controls of the I-SPY2 trial [17] enabled us to asses the pathologic response rate to ICI therapy based on MKS/ERS classification.